Director Declaration

Haleon PLC

28 September 2023

 

 

Haleon plc: Director Declaration

28 September 2023: In accordance with paragraph 9.6.14R of the Listing Rules of the UK Financial Conduct Authority, Haleon plc (the "Company") (LSE/NYSE: HLN) notes that Deirdre Mahlan, an Independent Non-Executive Director and Chair of the Audit & Risk Committee of the Company has been appointed Interim President, Chief Executive Officer and Chairperson of the Board of The Duckhorn Portfolio, Inc. (NYSE: NAPA) with immediate effect from 27 September 2023.

There is no further information to be disclosed in respect of paragraph 9.6.14.

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

 

END